Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.10
EPS est.
$-0.14
EPS surprise
+29.58%
1-day move
-3.15%
—
Est. EPS
$0.11
Est. Rev
$326M
Impl. Move
±7.3%
CytomX Therapeutics reported a narrower-than-expected loss per share, beating EPS estimates by nearly 30%. However, the stock fell by 3.15% following the earnings report, indicating investor concerns despite the EPS surprise. The lack of revenue figures and management commentary may have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +29.58% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.